Treats obsessive compulsive disorder (OCD). ANDA 220447, held by Zydus Pharms. Fluvoxamine Maleate.
As of Nov 16, 2026, ANDA 220447 (Fluvoxamine Maleate), held by Zydus Pharms, was first approved by FDA on Jul 21, 2026, with 0 approved supplements and 0 published complete response letters.
Fluvoxamine maleate extended-release capsules are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD). Efficacy was demonstrated in: One 12-week study with fluvoxamine maleate extended-release capsules in adults. Two 10-week studies with immediate-release (IR) fluvoxamine tablets in adults and one 10-week study with IR fluvoxamine tablets in children and adolescents ( 14.1, 14.3 ). One maintenance study with IR fluvoxamine tablets. 1.1 Obsessive Compulsive Disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 21, 2026 | Original application | Approved | None posted |
| Fluvoxamine Maleate100MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
| Fluvoxamine Maleate150MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters